CY1108663T1 - Αναστολεις της ενεργοποιησης συμπληρωματος - Google Patents
Αναστολεις της ενεργοποιησης συμπληρωματοςInfo
- Publication number
- CY1108663T1 CY1108663T1 CY20081101490T CY081101490T CY1108663T1 CY 1108663 T1 CY1108663 T1 CY 1108663T1 CY 20081101490 T CY20081101490 T CY 20081101490T CY 081101490 T CY081101490 T CY 081101490T CY 1108663 T1 CY1108663 T1 CY 1108663T1
- Authority
- CY
- Cyprus
- Prior art keywords
- factor
- antibody
- suspensions
- inhibitors
- molecules
- Prior art date
Links
- 230000000153 supplemental effect Effects 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000005714 functional activity Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά αναστολείς παράγοντα D, που συνδέονται προς τον παράγοντα D και δεσμεύουν την λειτουργική δραστικότητα του παράγοντα D στην ενεργοποίηση του συμπληρώματος. Οι αναστολείς περιλαμβάνουν μόρια αντισώματος, καθώς επίσης ομόλογα, ανάλογα και τροποποιημένες ή ληφθείσες μορφές αυτών, που συμπεριλαμβάνουν θραύσματα ανοσοσφαιρίνης, όπως Fab, (Fab')2 και Fv, μικρά μόρια, συμπεριλαμβανομένων πεπτιδίων, ολιγονουκλεοτιδίων, πεπτιδομιμητικών και οργανικών ενώσεων. Ένα μονοκλωνικό αντίσωμα το οποίο συνδέεται προς τον παράγοντα D και δέσμευσε την ικανότητα αυτού να ενεργοποιεί συμπλήρωμα δημιουργήθηκε και ορίσθηκε 166-32. Το υβρίδωμα που παράγει αυτό το αντίσωμα έχει αποτεθεί στη American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, υπό τον Αριθμό Κατάθεσης ΗΒ-12476.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7532898P | 1998-02-20 | 1998-02-20 | |
| EP99909512A EP1054693B8 (en) | 1998-02-20 | 1999-02-19 | Inhibitors of complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108663T1 true CY1108663T1 (el) | 2014-04-09 |
Family
ID=22124992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101490T CY1108663T1 (el) | 1998-02-20 | 2008-12-23 | Αναστολεις της ενεργοποιησης συμπληρωματος |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7439331B2 (el) |
| EP (6) | EP2848634A1 (el) |
| JP (1) | JP4437192B2 (el) |
| KR (1) | KR100425965B1 (el) |
| CN (2) | CN101298481A (el) |
| AT (1) | ATE412431T1 (el) |
| AU (1) | AU762050B2 (el) |
| BR (2) | BRPI9909220B1 (el) |
| CA (1) | CA2321140C (el) |
| CY (1) | CY1108663T1 (el) |
| DE (1) | DE69939813D1 (el) |
| DK (2) | DK2033659T3 (el) |
| ES (3) | ES2317689T3 (el) |
| HK (1) | HK1036016A1 (el) |
| NZ (1) | NZ506920A (el) |
| PT (1) | PT1054693E (el) |
| SI (2) | SI1054693T1 (el) |
| WO (1) | WO1999042133A1 (el) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| EP1585482A4 (en) * | 2002-09-25 | 2009-09-09 | Genentech Inc | NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS |
| EP2179742A1 (en) * | 2002-11-26 | 2010-04-28 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PT1713503E (pt) | 2004-02-10 | 2013-11-14 | Nat Jewish Health | Inibição do factor b, a via alternativa do complemento e métodos relacionados |
| BRPI0618160A2 (pt) | 2005-05-26 | 2011-08-16 | Univ Colorado | inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas |
| MX360959B (es) * | 2005-11-04 | 2018-11-23 | Genentech Inc | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares. |
| WO2007141004A1 (en) * | 2006-06-09 | 2007-12-13 | Bayer Healthcare Ag | Use of adipsin (adn) as a therapeutic or diagnostic target |
| EP2826788B1 (en) | 2006-06-21 | 2017-12-13 | MUSC Foundation for Research Development | Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules |
| RU2474589C9 (ru) | 2006-11-02 | 2019-08-15 | Дженентек, Инк. | Гуманизированные антитела к фактору d и их применения |
| EP1920781B1 (en) * | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| EP2148691B1 (en) * | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
| WO2008140653A2 (en) | 2007-03-14 | 2008-11-20 | Taligen Therapeutics, Inc. | Humaneered anti-factor b antibody |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| AU2008262048B2 (en) * | 2007-06-07 | 2013-09-26 | Genentech, Inc. | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| CA2767105A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CN102958535A (zh) | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
| KR20130080443A (ko) | 2010-05-14 | 2013-07-12 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 개선된 보체 수용체 ２(ｃｒ２) 표적 그룹들 |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
| CN116063483A (zh) | 2012-11-02 | 2023-05-05 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| ES2514165B1 (es) * | 2013-03-27 | 2015-09-09 | Consejo Superior De Investigaciones Científicas (Csic) | Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones |
| KR102448976B1 (ko) | 2013-08-07 | 2022-09-29 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
| CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| CA2944712A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
| CN106461661A (zh) * | 2014-05-02 | 2017-02-22 | Uab研究基金会 | 用于诊断和治疗脑膜炎的方法及组合物 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| TW201730211A (zh) | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| BR112018008673A2 (pt) | 2015-10-30 | 2018-11-27 | Genentech, Inc. | métodos para medir a atividade do fator d e para determinar a potência de um inibidor do fator d, método de triagem para um inibidor do fator d e kits |
| US20170137535A1 (en) * | 2015-10-30 | 2017-05-18 | Genentech, Inc. | Anti-factor d antibody formulations |
| IL260323B2 (en) | 2015-12-30 | 2025-01-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
| CA3053155A1 (en) | 2017-02-10 | 2018-08-16 | The Trustees Of The University Of Pennsylvania | Anti-factor d antibodies and uses thereof |
| AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5861156A (en) * | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
| US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| DE69533921T2 (de) | 1994-03-23 | 2005-12-01 | Alexion Pharmaceuticals, Inc., New Haven | Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5679345A (en) * | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
| US7112327B2 (en) * | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
-
1999
- 1999-02-19 EP EP14168816.8A patent/EP2848634A1/en not_active Withdrawn
- 1999-02-19 DK DK08018816.2T patent/DK2033659T3/en active
- 1999-02-19 ES ES99909512T patent/ES2317689T3/es not_active Expired - Lifetime
- 1999-02-19 EP EP15185734.9A patent/EP3056516A1/en not_active Withdrawn
- 1999-02-19 PT PT99909512T patent/PT1054693E/pt unknown
- 1999-02-19 JP JP2000532147A patent/JP4437192B2/ja not_active Expired - Lifetime
- 1999-02-19 EP EP99909512A patent/EP1054693B8/en not_active Expired - Lifetime
- 1999-02-19 DE DE69939813T patent/DE69939813D1/de not_active Expired - Lifetime
- 1999-02-19 BR BRPI9909220A patent/BRPI9909220B1/pt unknown
- 1999-02-19 BR BR9909220-4A patent/BR9909220A/pt not_active IP Right Cessation
- 1999-02-19 EP EP17156521.1A patent/EP3260467A1/en not_active Withdrawn
- 1999-02-19 CN CNA2007103002136A patent/CN101298481A/zh active Pending
- 1999-02-19 SI SI9931018T patent/SI1054693T1/sl unknown
- 1999-02-19 AU AU28700/99A patent/AU762050B2/en not_active Expired
- 1999-02-19 CN CNB998052566A patent/CN100366293C/zh not_active Expired - Lifetime
- 1999-02-19 AT AT99909512T patent/ATE412431T1/de active
- 1999-02-19 DK DK99909512T patent/DK1054693T3/da active
- 1999-02-19 SI SI9931073T patent/SI2033659T1/sl unknown
- 1999-02-19 WO PCT/US1999/003566 patent/WO1999042133A1/en active IP Right Grant
- 1999-02-19 EP EP08018816.2A patent/EP2033659B1/en not_active Expired - Lifetime
- 1999-02-19 EP EP10182251.8A patent/EP2277920B1/en not_active Expired - Lifetime
- 1999-02-19 ES ES08018816.2T patent/ES2446930T3/es not_active Expired - Lifetime
- 1999-02-19 ES ES10182251.8T patent/ES2488819T3/es not_active Expired - Lifetime
- 1999-02-19 KR KR10-2000-7008454A patent/KR100425965B1/ko not_active IP Right Cessation
- 1999-02-19 CA CA2321140A patent/CA2321140C/en not_active Expired - Lifetime
- 1999-02-19 NZ NZ506920A patent/NZ506920A/en not_active IP Right Cessation
-
2001
- 2001-10-04 HK HK01106981A patent/HK1036016A1/xx not_active IP Right Cessation
-
2006
- 2006-06-29 US US11/478,089 patent/US7439331B2/en not_active Expired - Fee Related
-
2008
- 2008-12-23 CY CY20081101490T patent/CY1108663T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108663T1 (el) | Αναστολεις της ενεργοποιησης συμπληρωματος | |
| ATE435873T1 (de) | Anti-c2/c2a inhibitoren zur komplement aktivierung | |
| HK1225741A1 (zh) | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 | |
| NO2006008I2 (no) | Natalizumab, anti alfa-4 integrin humanized monoclonal antibody | |
| KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
| RS80704A (en) | ANTI- av?6.ANTIBODIES | |
| HRP20090527T1 (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| NO20063224L (no) | Anti-MPL-antistoff | |
| EA200100698A1 (ru) | Моноклональные антитела человека к ctla-4 | |
| ATE421976T1 (de) | Fab fragmentbibliotheken und verfahren für deren verwendung | |
| ATE509955T1 (de) | Humanisierte kollagen-antikörper und damit verbundene verfahren | |
| EA200870072A1 (ru) | ПРОТИВОВОСПАЛИТЕЛЬНЫЕ dAb | |
| EP1411962A4 (en) | TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY | |
| IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same | |
| EP1468022A4 (en) | NEW MONOCLONAL ANTIBODY AND LARVAL NEMATODIAN ANTIGENS | |
| HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk | |
| SE9501302D0 (sv) | Antibodies for use in cancertherapy and diagnosis |